(Q45168352)

English

Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study

scientific article published in December 2004

Statements

Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study (English)
EORTC-New Drug Development Group/New Drug Development Program

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit